Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Halberd Receives Patent for Treatment of Cockayne Syndrome - May Provide Pathway to Slow Aging

JACKSON CENTER, PA / ACCESSWIRE / August 25, 2021 / Halberd Corporation (OTC PINK:HALB) received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome.

Cockayne Syndrome is a fatal autosomal recessive neurodegenerative disorder which causes premature aging and severely impaired development of the nervous system. Cockayne Syndrome is one of only a few known diseases which cause premature aging. Halberd's scientific team and patent counsel believe that this is one of the first granted patents which could slow the aging process. This intellectual property also greatly strengthens the existing intellectual property of Halberd. This patent application utilizes Halberd's patented extra-corporeal methodology for the development of treatments for infectious diseases, such as PTSD, CTE, Alzheimer's Disease, and others.

Mitchell S. Felder, M.D., Halberd's Chief Technology Officer, and board certified neurologist, stated, "From time immemorial, mankind has dreamed of finding a method for slowing the aging process. I believe that this granted patent may be a first step in achieving that dream. It may also potentially open the door for the treatment of a great many other neurodegenerative maladies (Alzheimer's Disease, Parkinson's Disease, PTSD, CTE, etc.). In part, this granted patent teaches a technique for precisely controlling the exact pico-gram/ml concentration of Death-Associated Protein 1 (DAP1). Obviously, less DAP1 may lead to reduced premature death(s)."

William A. Hartman, Chairman, President & CEO added, "The potential to slow the aging process presents phenomenal possibilities! The beautiful part of Halberd's technology is that all of our work on different major diseases involves the same fundamental elements - extracorporeal (outside the body) application, antibodies, antigens, the same university partners, Chemical Bonding, Lasers, and Radio Frequency elimination techniques. This commonality allows us to pursue a wide variety of major diseases by altering only our created antibodies and the target antigens. That makes Halberd equivalent of a huge biomedical corporation with a massive collection of patented intellectual property covering multiple major diseases. This makes Halberd's technology similar to a screwdriver with interchangeable tips - it uses the same basic tool."

Hartman continued, "This Cockayne Syndrome/ Aging patent could be the first step in the discovery of an actual "Fountain of Youth". Halberd's strategy has been to pursue those diseases that are: 1) Major; 2) Have no known effective cures; 3) Are within our capability to deliver in the short term utilizing our existing technology, and 4) Covered by our strong patent protection. We are working to revolutionize medicine, not just to find another treatment!

Equally important - we are building the foundation of common thread of strategies with profound prospects for universal application, addressing numerous medical maladies."

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to numerous patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis. The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders."

SOURCE: Halberd Corporation



View source version on accesswire.com:
https://www.accesswire.com/661250/Halberd-Receives-Patent-for-Treatment-of-Cockayne-Syndrome--May-Provide-Pathway-to-Slow-Aging

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.